PXN and lip and oral cavity carcinoma: In conclusion, the study offers compelling evidence supporting salivary paxillin as a reliable biomarker for oral cancer, emphasizing its potential clinical significance in early diagnosis and prognosis while advocating for further research to validate its broader diagnostic utility.